Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Non-Current Debt (2023 - 2025)

Goldenwell Biotech's Non-Current Debt history spans 3 years, with the latest figure at $95588.0 for Q1 2025.

  • For Q1 2025, Non-Current Debt changed N/A year-over-year to $95588.0; the TTM value through Mar 2025 reached $95588.0, changed N/A, while the annual FY2024 figure was $95588.0, 26.46% up from the prior year.
  • Non-Current Debt reached $95588.0 in Q1 2025 per GWLL's latest filing, roughly flat from $95588.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $95588.0 in Q4 2024 to a low of $75588.0 in Q4 2023.
  • Average Non-Current Debt over 3 years is $88921.3, with a median of $95588.0 recorded in 2024.
  • The largest YoY upside for Non-Current Debt was 26.46% in 2024 against a maximum downside of 26.46% in 2024.
  • A 3-year view of Non-Current Debt shows it stood at $75588.0 in 2023, then increased by 26.46% to $95588.0 in 2024, then changed by 0.0% to $95588.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Non-Current Debt are $95588.0 (Q1 2025), $95588.0 (Q4 2024), and $75588.0 (Q4 2023).